This Article Full Text Full Text (PDF) All Versions of this Article: 113/21/2485    most recent CIRCULATIONAHA.105.570796v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bunch, T. J. Articles by Packer, D. L. Search for Related Content PubMed PubMed Citation Articles by Bunch, T. J. Articles by Packer, D. L. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Arrhythmia Related Collections Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2006;113:2485-2494.)
© 2006 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Impact of Transforming Growth Factor-ß1 on Atrioventricular Node Conduction Modification by Injected Autologous Fibroblasts in the Canine Heart

T. Jared Bunch, MD; Srijoy Mahapatra, MD; G. Keith Bruce, MD; Susan B. Johnson, BS; Dylan V. Miller, MD; Benjamin D. Horne, PhD, MPH; Xiao-Li Wang, MD, PhD; Hon-Chi Lee, MD, PhD; Noel M. Caplice, MD, PhD; Douglas L. Packer, MD

From the Divisions of Cardiovascular Disease, Department of Internal Medicine (T.J.B., S.M., G.K.B., S.B.J., X.-L.W., H.-C.L., N.M.C., D.L.P.) and Anatomic Pathology (D.V.M.), Mayo Clinic, Rochester, Minn, and Cardiovascular Department (B.D.H.), LDS Hospital, Salt Lake City, Utah.

Correspondence to Douglas L. Packer, MD, Mayo Clinic, St. Mary’s Hospital, 1216 2nd St SW, AL 2-416, Rochester, MN 55902. E-mail packer.douglas{at}mayo.edu

Received June 22, 2005; revision received February 17, 2006; accepted March 9, 2006.

Background— Atrioventricular (AV) nodal ablation for management of atrial fibrillation (AF) is irreversible and requires permanent pacemaker implantation. We hypothesized that as an alternative, implantation of autologous fibroblasts in the perinodal region would focally modify AV nodal conduction and that this modulation would be enhanced by pretreatment with transforming growth factor-ß1 (TGF-ß1), a stimulant of fibroblasts.

Methods and Results— Skin biopsies were taken from 12 mongrel dogs, and derived fibroblasts were dissociated and grown in culture for 2 weeks. Multiple injections (0.25 mL) were made through an 8F NOGA catheter along the fast/slow AV nodal pathways as guided by an electroanatomic mapping system. Seven dogs received fibroblasts alone (1x10⁶ cells/mL), 7 dogs received TGF-ß1 (5 µg), 4 dogs received fibroblasts and TGF-ß1 (1x10⁶ cells/mL+5 µg), and 4 dogs received saline only. AV node function was assessed at baseline and after 4 weeks. Saline (80 mL) with assigned therapy (0.25 mL per injection) was injected into the peri-AV nodal region in each dog. At baseline, the AH interval (66±3 ms) and the average RR interval (331±17 ms) in pacing-induced AF were similar in each cohort. The increase in AH interval in normal sinus rhythm was longer after fibroblast (23±4 versus 5±5 ms; P=0.05) and fibroblast plus TGF-ß1 (50±5 versus 5±5 ms; P<0.001) injections than with saline alone, with similar findings during high right atrium and distal coronary sinus pacing. The AH interval was not significantly increased after TGF-ß1 injections. The AH interval was significantly longer after fibroblast plus TGF-ß1 injections than with either therapy (TGF-ß1 or fibroblasts) alone. The RR interval during AF was increased in dogs that received fibroblasts alone (110±36 versus –41±34 ms) and to a greater extent with the addition of TGF-ß1 (294±108 versus –41±34 ms). No AV block was seen in any cohort at 4 weeks. Labeled fibroblasts that expressed vimentin were identified in all dogs that received cell injections at 4 weeks.

Conclusions— AV nodal modification can be achieved with injected fibroblasts without the creation of AV block. The effect on AV node conduction is substantially enhanced by pretreatment of fibroblasts with TGF-ß1. These data have therapeutic potential for the management of rapid ventricular rate during AF without pacemaker implantation.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				M. C. Waghabi, E. M. de Souza, G. M. de Oliveira, M. Keramidas, J.-J. Feige, T. C. Araujo-Jorge, and S. Bailly Pharmacological Inhibition of Transforming Growth Factor {beta} Signaling Decreases Infection and Prevents Heart Damage in Acute Chagas' Disease Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4694 - 4701. [Abstract] [Full Text] [PDF]

				L. Yankelson, Y. Feld, T. Bressler-Stramer, I. Itzhaki, I. Huber, A. Gepstein, D. Aronson, S. Marom, and L. Gepstein Cell Therapy for Modification of the Myocardial Electrophysiological Substrate Circulation, February 12, 2008; 117(6): 720 - 731. [Abstract] [Full Text] [PDF]

				H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm Management of atrial fibrillation in patients with heart failure Eur. Heart J., November 1, 2007; 28(21): 2568 - 2577. [Abstract] [Full Text] [PDF]

				K. F. Kwaku Cell Therapy for Rate Control in Atrial Fibrillation: A New Approach to an Old Problem Circulation, May 30, 2006; 113(21): 2474 - 2476. [Full Text] [PDF]